A Phase 2 Study of Momelotinib, a Potent JAK1 and JAK2 inhibitor, in Patients With Polycythemia Vera or Essential Thrombocythemia

This phase 2, open-label, randomized study evaluated the efficacy and safety of oral once-daily momelotinib (100 mg and 200 mg) for the treatment of polycythemia vera and essential thrombocythemia. Ultimately, the study was terminated due to limited efficacy.

 Leuk Res

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.